Celecoxib plus standard treatment for bile duct cancer
Part of Cancer clinical trials.
This study tests whether adding celecoxib (an anti-inflammatory drug) to standard immunotherapy and chemotherapy improves outcomes for people with a specific type of bile duct cancer that has high levels of a protein called CK5/6. It aims to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of intrahepatic cholangiocarcinoma (bile duct cancer within the liver).
- Your cancer must be unresectable, locally advanced, or have spread to other parts of the body.
- You must not have received prior systemic treatment for advanced disease.
- You must have at least one measurable tumor on imaging.
- Your tumor must express a protein called CK5/6 at a certain level (H-score greater than 1).
- You must have adequate organ and bone marrow function.
- If you have bile duct blockage, it must be drained and stable before starting treatment.
- You must be willing and able to provide written informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a three-drug combination (TACE plus two immune-related drugs) against a standard chemo-immunotherapy regimen for people with a liver cancer that can't be surgically removed. It aims to see if the new approach can shrink tumors and improve outcomes.
This study tests additional treatment given after surgery to remove high-risk intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to reduce the chance the cancer comes back and improve survival in patients whose tumors had concerning features.
This trial tests whether adding an immunotherapy drug (toripalimab) to standard chemotherapy before surgery can improve outcomes for people with intrahepatic cholangiocarcinoma that can be surgically removed. It's for patients who haven't had prior treatment for their cancer and are in good overall health.
This trial tests giving chemotherapy (cisplatin and gemcitabine) combined with an immunotherapy drug (rilvegostomig) before and after surgery for a type of bile duct cancer called intrahepatic cholangiocarcinoma that has a high risk of coming back. The goal is to see if this combination can reduce the chance of cancer returning.
This trial tests a combination of chemotherapy directly to the liver, a targeted therapy pill, and an immunotherapy drug for people with advanced bile duct or gallbladder cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests a combination of immunotherapy (adebrelimab) and chemotherapy drugs for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that hasn't been treated yet. It aims to see if adding a targeted therapy (lenvatinib) improves outcomes.
Hear when a new Intrahepatic Cholangiocarcinoma (Icc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.